SCPA.L Regulatory News (SCPA)

LEI No. 213800QIPVTK5ES5UU36

22 January 2019

Scapa Group plc

('Scapa' or 'the Company')

Directorate Appointments

Further strengthening the Board with the appointment of three directors, including two healthcare experts reflecting the Company's increased focus in this high-growth market.  

Scapa Group plc (AIM: SCPA) is pleased to announce three appointments to the Company's Board of Directors, with effect from 21 January 2019.

Joe Doherty

Joe Doherty joins the Board as an Executive Director and the Company as Healthcare President-Designate. Joe will become Healthcare President on 1 April 2019 following Joe Davin's planned retirement on 31 March 2019. 

Joe's most recent role was President of Olympus Surgical Technologies America responsible for the strategic marketing, development and manufacturing of devices for a number of surgical specialties. He was also a member of the Olympus Corporation of the Americas Executive Committee. Prior to joining Olympus in 2015, Joe spent 24 years with Johnson & Johnson (J&J). During his tenure at J&J, Joe was Vice President of Integration, responsible for the largest acquisition in the company's history (US$20bn acquisition of Synthes), and a member of the Executive Team of DePuy Synthes, a US$10bn orthopedic and neurosurgery device company. While at J&J, Joe was also Head of R&D and a member of the Neuro Franchise worldwide management board, responsible for the global neurosurgical/neurovascular portfolio of products.  Joe is a graduate of the United States Military Academy (West Point), with a Bachelor of Science in Engineering, and has an MBA from Nichols College. 

Sevan Demirdogen

Sevan Demirdogen, current President and Executive Vice President of Scapa, joins the Board as an Executive Director.

Sevan joined Scapa in April 2018 from Illinois Tool Works (ITW) where he held various roles since 1982. During the past 10 years, Sevan has been the Group President of ITW Stokvis, one of the world's largest independent tape converters with circa US$250m in revenue, responsible for 22 sites across 18 countries with over 1,000 employees.

Juliet Thompson

Juliet Thompson joins the Board as an Independent Non-Executive Director.

Juliet will chair the Remuneration Committee and will also be a member of the Board's Audit and Risk, and Nomination Committees. Juliet is currently a board member of a number of internationally listed medical device, development and diagnostic companies, including being Non-Executive Director of Vectura Group plc, GI Dynamics Inc and Novacyt SA, and Deputy Chairman of Nexstim plc. She was previously Non-Executive Chairman and Director of the Board of Premier Veterinary Group plc until 1 March 2018. Juliet has spent over 20 years actively involved in the life sciences sector working as an investment banker and strategic advisor to healthcare companies in Europe. Juliet has a BSc in economics and is a chartered accountant.

Larry Pentz, Scapa's Chairman, said:

"On behalf of the Board, I am delighted to welcome Joe, Sevan and Juliet to the Scapa Board of Directors. Their breadth of knowledge and experience will bring additional perspectives and depth to our Board while our business continues to grow and expand within the healthcare and industrial markets. The Board would like to thank Joe Davin, Healthcare President, whose leadership has taken our healthcare business from concept to a business with over £150 million revenue and recognised as a trusted strategic partner to many world leading healthcare companies."

The Company makes the following disclosures in relation to Joe Doherty's appointment in accordance with paragraph (g) of Schedule Two of the AIM Rules for Companies:

1. Director's full name: Joseph Edward Doherty (known as Joe Doherty)

Director's age: 53 years

2 Other directorships/partnerships held during the last five years, including appointment and, where appropriate, resignation dates:

3. Shareholding: Mr Doherty does not hold any shares in the Company.

4. Other information: There is no other information required to be disclosed in relation to Mr Doherty under paragraph (g) of Schedule Two of the AIM Rules for Companies.

The Company makes the following disclosures in relation to Sevan Demirdogen's appointment in accordance with paragraph (g) of Schedule Two of the AIM Rules for Companies:

1. Director's full name: Sevan Demirdogen

Director's age: 58 years

2 Other directorships/partnerships held during the last five years, including appointment and, where appropriate, resignation dates:

3. Shareholding: Mr Demirdogen holds 5,000 shares in the Company.

4. Other information: There is no other information required to be disclosed in relation to Mr Demirdogen under paragraph (g) of Schedule Two of the AIM Rules for Companies.

The Company makes the following disclosures in relation to Juliet Thompson's appointment in accordance with paragraph (g) of Schedule Two of the AIM Rules for Companies:

1. Director's full name: Juliet Thompson

 Director's age: 52 years

2 Other directorships/partnerships held during the last five years, including appointment and, where appropriate, resignation dates:

3. Shareholding: Ms Thompson does not hold any shares in the Company.

4. Other information: There is no other information required to be disclosed in relation to Ms Thompson under paragraph (g) of Schedule Two of the AIM Rules for Companies.

For further information:

Scapa Group plc: +44 (0) 161 301 7400

Wendy Baker

Group General Counsel and Company Secretary

Numis Securities Limited: +44 (0) 20 7260 1000

Mark Lander

Richard Thomas (Nominated Adviser)

Freddie Naylor-Leyland

Berenberg (Joint Broker) +44(0) 20 3207 7800

Chris Bowman

FTI Consulting (media relations): +44 (0) 20 3727 1000

Brett Pollard

Victoria Foster Mitchell